An oncology consultation. Editorial illustration.
When chemotherapy helps someone survive breast cancer, what might the treatment mean for their health decades later? A study in JAMA Network Open used a computer model to explore one possibility: treatment-related cellular aging could affect the long-term risk of dying from causes other than breast cancer. The model produced large differences under some assumptions. Those figures are projections and cannot be used to predict an individual’s survival.
Evidence level Early Research. The life-year estimates came from a computer simulation informed by human data.
How the model represented cellular aging
Chemotherapy can damage healthy cells as well as cancer cells. Some damaged cells enter senescence, a state in which they stop dividing and can continue releasing signals that affect nearby tissue. The researchers used prior measurements of p16INK4a, a marker associated with senescence, to represent differences in biological aging after treatment.
The team adapted a breast cancer simulation from the Cancer Intervention and Surveillance Modeling Network. Its main analysis began with 400 million simulated US women and evaluated survivors diagnosed between ages 30 and 79. The same simulated population was evaluated under two scenarios: a more cytotoxic anthracycline-based regimen and a less cytotoxic nonanthracycline regimen. The researchers assumed that the treatment-related increase in senescence persisted and affected mortality from causes other than breast cancer.
What the life-year figures mean
Across ages, the model projected 9.4 life-years lost to the assumed aging effect for the anthracycline regimen and 1.8 for the nonanthracycline regimen at the median of the modeled biological-age distribution. That is a 7.6-year difference in the projected losses from each regimen’s own baseline. The model’s estimates of total remaining life at that percentile were 25.0 and 29.7 years, respectively.
The distinction matters because the two regimens started with different expected survival based on chronological age alone. The model also estimated larger aging-related losses among women diagnosed younger. For ages 30 to 39, those losses were 11.7 and 2.1 years, respectively. None of these lifetime differences came from following patients for decades.
Why the cancer treatment benefit still matters
In the Anthracyclines in Early Breast Cancer trials used for validation, anthracycline-based therapy yielded better breast cancer survival, and the groups showed no difference in all-cause mortality over eight years. The simulation reproduced that pattern over the same period. Chemotherapy remains an essential, evidence-based treatment when indicated. This model does not provide grounds to avoid, delay or discontinue it.
The researchers relied on one marker of cellular aging and had insufficient data to model some newer therapies or hormonal therapy. The long-term projections also depend on how long the change in that marker lasts. The study could not establish whether patients recover some of that change over time.
What survivorship studies can test next
Following survivors over time with repeated biomarker measurements, health assessments and clinical outcomes could show whether these markers identify people who would benefit from closer follow-up. The immediate value of the model is to point to questions that survivorship studies can test alongside the established benefits of cancer treatment.
Related reading on what aging clocks measured in a breast cancer survivorship trial.
Original research
Sarkar S, Sedrak MS, Carroll JE, et al. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Network Open, November 10, 2026.